Sunshine Biopharma Inc (SBFM) - Net Assets

Latest as of September 2025: $24.20 Million USD

Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has net assets worth $24.20 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.49 Million) and total liabilities ($7.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sunshine Biopharma Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$24.20 Million
% of Total Assets	76.85%
Annual Growth Rate	55.17%
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	3362.21

Sunshine Biopharma Inc - Net Assets Trend (2007–2024)

This chart illustrates how Sunshine Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore SBFM current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Sunshine Biopharma Inc (2007–2024)

The table below shows the annual net assets of Sunshine Biopharma Inc from 2007 to 2024. For live valuation and market cap data, see market value of Sunshine Biopharma Inc.

Year	Net Assets	Change
2024-12-31	$23.50 Million	+10.81%
2023-12-31	$21.21 Million	-1.94%
2022-12-31	$21.63 Million	+10117.97%
2021-12-31	$211.66K	+122.17%
2020-12-31	$-954.84K	-29.84%
2019-12-31	$-735.38K	-1219.01%
2018-12-31	$-55.75K	+90.28%
2017-12-31	$-573.36K	-173.42%
2016-12-31	$-209.70K	+64.88%
2015-12-31	$-597.04K	-54.04%
2014-12-31	$-387.58K	-4926.98%
2013-12-31	$-7.71K	-110.95%
2012-12-31	$70.43K	-31.63%
2011-12-31	$103.00K	-47.51%
2010-12-31	$196.22K	+100.63%
2009-12-31	$97.80K	+652.24%
2008-12-31	$-17.71K	-232.21%
2007-12-31	$13.39K	--

Equity Component Analysis

This analysis shows how different components contribute to Sunshine Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 6902665200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	$2.58K	0.01%
Other Comprehensive Income	$-829.96K	-3.53%
Other Components	$93.37 Million	397.30%
Total Equity	$23.50 Million	100.00%

Sunshine Biopharma Inc Competitors by Market Cap

The table below lists competitors of Sunshine Biopharma Inc ranked by their market capitalization.

Company	Market Cap
Hollywood Bowl Group PLC LSE:BOWL	$5.18 Million
SUNation Energy Inc. NASDAQ:SUNE	$5.18 Million
Golden Tobacco Limited NSE:GOLDENTOBC	$5.18 Million
Mangoceuticals, Inc. Common Stock NASDAQ:MGRX	$5.18 Million
Cape Range Ltd AU:CAG	$5.17 Million
Megapower Makmur TBK PT JK:MPOW	$5.17 Million
Vintage Energy Ltd AU:VEN	$5.17 Million
abrdn Asian Income Fund Limited LSE:AAIF	$5.17 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sunshine Biopharma Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 21,207,361 to 23,500,754, a change of 2,293,393 (10.8%).
Net loss of 5,134,000 reduced equity.
Share repurchases of 3,139,651 reduced equity.
New share issuances of 8,522,411 increased equity.
Other comprehensive income decreased equity by 1,526,064.
Other factors increased equity by 3,570,697.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	$-5.13 Million	-21.85%
Share Repurchases	$3.14 Million	-13.36%
Share Issuances	$8.52 Million	+36.26%
Other Comprehensive Income	$-1.53 Million	-6.49%
Other Changes	$3.57 Million	+15.19%
Total Change	$-	10.81%

Book Value vs Market Value Analysis

This analysis compares Sunshine Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.03x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2007-12-31	$28.62	$1.06	x
2008-12-31	$-37.84	$1.06	x
2009-12-31	$4.17	$1.06	x
2010-12-31	$128.08	$1.06	x
2011-12-31	$42.28	$1.06	x
2012-12-31	$27.42	$1.06	x
2013-12-31	$-2.56	$1.06	x
2014-12-31	$-105.44	$1.06	x
2015-12-31	$-390.74	$1.06	x
2016-12-31	$-78834.59	$1.06	x
2017-12-31	$-13.14	$1.06	x
2018-12-31	$-3.66	$1.06	x
2019-12-31	$-416.65	$1.06	x
2020-12-31	$-1102.58	$1.06	x
2021-12-31	$162.07	$1.06	x
2022-12-31	$2849.48	$1.06	x
2023-12-31	$1743.31	$1.06	x
2024-12-31	$33.49	$1.06	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sunshine Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -21.85%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -14.72%
• Asset Turnover: 1.14x
• Equity Multiplier: 1.30x
Recent ROE (-21.85%) is above the historical average (-443.60%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	-97.96%	0.00%	0.00x	1.11x	$-14.46K
2008	0.00%	0.00%	0.00x	0.00x	$-29.33K
2009	-25.58%	0.00%	0.00x	1.15x	$-34.80K
2010	-273.87%	0.00%	0.00x	1.06x	$-557.00K
2011	-539.99%	0.00%	0.00x	1.03x	$-566.50K
2012	-1005.24%	0.00%	0.00x	1.91x	$-714.99K
2013	0.00%	0.00%	0.00x	0.00x	$-2.49 Million
2014	0.00%	0.00%	0.00x	0.00x	$-1.90 Million
2015	0.00%	-96779.86%	0.00x	0.00x	$-1.59 Million
2016	0.00%	0.00%	0.00x	0.00x	$-3.48 Million
2017	0.00%	0.00%	0.00x	0.00x	$-982.90K
2018	0.00%	-482.11%	0.39x	0.00x	$-2.15 Million
2019	0.00%	-7860.85%	0.22x	0.00x	$-1.59 Million
2020	0.00%	-3898.74%	0.07x	0.00x	$-2.69 Million
2021	-5875.41%	-5444.21%	0.10x	10.41x	$-12.46 Million
2022	-123.66%	-615.37%	0.15x	1.37x	$-28.91 Million
2023	-21.25%	-18.70%	0.88x	1.29x	$-6.63 Million
2024	-21.85%	-14.72%	1.14x	1.30x	$-7.48 Million

Industry Comparison

This section compares Sunshine Biopharma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $236,113,024
Average return on equity (ROE) among peers: -47.06%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Sunshine Biopharma Inc (SBFM)	$24.20 Million	-97.96%	0.30x	$5.18 Million
Aurora Cannabis Inc (ACB)	$602.92 Million	-11.50%	0.39x	$197.35 Million
Akanda Corp (AKAN)	$-3.83 Million	0.00%	0.00x	$1.51 Million
Akebia Ther (AKBA)	$74.01 Million	-330.87%	6.15x	$340.21 Million
Alkermes Plc (ALKS)	$54.20 Million	-73.99%	0.03x	$4.62 Billion
Amylyx Pharmaceuticals Inc (AMLX)	$-25.36 Million	0.00%	0.00x	$1.77 Billion
Amphastar P (AMPH)	$639.42 Million	21.51%	1.37x	$959.02 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)	$346.79 Million	-104.36%	9.57x	$3.81 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)	$344.93 Million	26.40%	10.61x	$3.57 Billion
Anika Therapeutics Inc (ANIK)	$287.08 Million	1.44%	0.21x	$199.00 Million
ANI Pharmaceuticals Inc (ANIP)	$40.96 Million	0.73%	0.09x	$1.80 Billion

About Sunshine Biopharma Inc

NASDAQ:SBFM USA Drug Manufacturers - Specialty & Generic

Market Cap

$5.18 Million

Market Cap Rank

#28306 Global

#5577 in USA

Share Price

$1.06

Change (1 day)

+9.63%

52-Week Range

$0.96 - $2.20

All Time High

$1000000.00